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Background Necitumumab is a second-generation, recombinant, human immunoglobulin G1 EGFR 
antibody. In this study, we aimed to compare treatment with necitumumab plus gemcitabine and 
cisplatin versus gemcitabine and cisplatin alone in patients with previously untreated stage IV 
squamous non-small-cell lung cancer. 
Methods We did this open-label, randomised phase 3 study at 184 investigative sites in 26 countries. 
Patients aged 18 years or older with histologically or cytologically confirmed stage IV squamous non-
small-cell lung cancer, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-
2 and adequate organ function and who had not received previous chemotherapy for their disease 
were eligible for inclusion. Enrolled patients were randomly assigned centrally 1:1 to a maximum of six 
3-week cycles of gemcitabine and cisplastin chemotherapy with or without necitumumab according to 
a block randomisation scheme (block size of four) by a telephone-based interactive voice response 
system or interactive web response system. Chemotherapy was gemcitabine 1250 mg/m
2
 
administered intravenously over 30 min on days 1 and 8 of a 3-week cycle and cisplatin 75 mg/m
2
 
administered intravenously over 120 min on day 1 of a 3-week cycle. Necitumumab 800 mg, 
administered intravenously over a minimum of 50 min on days 1 and 8, was continued after the end of 
chemotherapy until disease progression or intolerable toxic side-effects occurred. Randomisation was 
stratified by ECOG performance status and geographical region. Neither physicians nor patients were 
masked to group assignment because of the expected occurrence of acne-like rash—a class effect of 
EGFR antibodies—that would have unmasked most patients and investigators to treatment. The 
primary endpoint was overall survival, analysed by intention to treat. We report the final clinical 
analysis. This study is registered with ClinicalTrials.gov, number NCT00981058. 
Findings Between Jan 7, 2010, and Feb 22, 2012, we enrolled 1093 patients and randomly assigned 
them to receive necitumumab plus gemcitabine and cisplatin (n=545) or gemcitabine and cisplatin 
(n=548). Overall survival was significantly longer in the necitumumab plus gemcitabine and cisplatin 
group than in the gemcitabine and cisplatin alone group (median 11 · 5 months [95% CI 10·4-12·6]) vs 
9·9 months [8·9-11·1]; stratified hazard ratio 0·84 [95% CI 0∙74-0∙96; p=0∙01]). In the necitumumab 
plus gemcitabine and cisplatin group, the number of patients with at least one grade 3 or worse 
adverse event was higher (388 [72%] of 538 patients) than in the gemcitabine and cisplatin group (333 
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[62%] of 541), as was the incidence of serious adverse events (257 [48%] of 538 patients vs 203 
[38%] of 541). More patients in the necitumumab plus gemcitabine and cisplatin group had grade 3-4 
hypomagnesaemia (47 [9%] of 538 patients in the necitumumab plus gemcitabine and cisplatin group 
vs six [1%] of 541 in the gemcitabine and cisplatin group) and grade 3 rash (20 [4%] vs one [<1%])∙ 
Including events related to disease progression, adverse events with an outcome of death were 
reported for 66 (12%) of 538 patients in the necitumumab plus gemcitabine and cisplatin group and 57 
(11%) of 541 patients in the gemcitabine and cisplatin group; these were deemed to be related to 
study drugs in 15 (3%) and ten (2%) patients, respectively. Overall, we found that the safety profile of 
necitumumab plus gemcitabine and cisplatin was acceptable and in line with expectations. 
Interpretation Our findings show that the addition of necitumumab to gemcitabine and cisplatin 
chemotherapy improves overall survival in patients with advanced squamous non-small-cell lung 
cancer and represents a new first-line treatment option for this disease. 
Funding Eli Lilly and Company. 
 
RESEARCH IN CONTEXT 
Evidence before this study 
In the development of the study design and protocol, we did a systematic review of the published 
scientific literature. We searched PubMed, with no time restrictions; abstracts of major oncology 
congresses; and trial websites including ClinicalTrials.gov, for English-language preclinical reports and 
clinical trials assessing chemotherapy in patients with lung cancer, EGFR therapies in these patients, 
and the combination of these methods. Search terms for clinical trials of moleculartargeted therapies 
included "lung cancer" and "EGFR". Clinical data in support of this trial included a phase 1 
pharmacological study of necitumumab in patients with advanced solid malignancies that showed 
necitumumab was well tolerated and had anti-tumour activity at therapeutically relevant trough 
concentrations. On the basis of our review of the literature and discussions with clinicians, 
researchers, and regulatory bodies, we postulated that combining chemotherapy with an EGFR-
targeted therapy might improve treatment efficacy in patients with advanced squamous non-small-cell 
lung cancer. 
Added value of this study 
Ourstudy shows a significant reduction in risk of death and an overall acceptable safety profile in 
patients who received necitumumab plus gemcitabine and cisplatin. The improvement in overall 
survival in this patient population compared with those who received gemcitabine and cisplatin 
chemotherapy alone was supported by a corresponding significant improvement in progression-free 
survival and a high consistency of the effectsof the treatments in subgroup analyses. We recorded no 
evidence for a predictive association between an EGFR H-score of 200 or more and survival for 
necitumumab plus gemcitabine and cisplatin in this setting. 
Implications of all the available evidence 
The SQUIRE trial design was appropriate forthe first-line treatment of a patient population with 
squamous non-small-cell lung cancer and can be generalised to clinical practice. The results confirm 
the benefit of the addition of an EGFR antibody to standard chemotherapy in this setting and represent 
clinically meaningful progress in the treatment of squamous non-small-cell lung cancer. 
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INTRODUCTION 
Squamous cell carcinomas account for 30% of non-small-cell lung cancers worldwide.
1
 In addition to 
histopathological differences, the mutational profiles of squamous and non-squamous non-small-cell 
lung cancers are distinctive, with both of these aspects potentially affecting treatment selection.
2
 For 
patients with squamous non-small-cell lung cancer, although some potentially targetable molecular 
lesions have been identified in tumours,
1,3
 including PIK3CA amplification, FGFR1 amplification, MET 
amplification, and DDR2 mutation, none of these biomarkers have yet been validated in this setting as 
predictive for particular targeted therapies, and available first-line regimens have remained essentially 
unchanged for the past two decades. In general, such regimens comprise a platinum-based doublet of 
cisplatin or carboplatin combined with gemcitabine, vinorelbine, or a taxane.
1,4
 By contrast, for patients 
with non-squamous non-small-cell lung cancer, the availability of pemetrexed and bevacizumab as 
components of first-line or maintenance regimens has widened the choice of possible treatments and 
provided the opportunity to improve overall survival in this patient group.
5-9
 Additionally, a few recurring 
somatic tumour mutations have been described in adenocarcinomas, offering the potential for 
selective pathway-directed systemic therapy.
10-12
 In particular, EGFR mutations and ALK 
translocations are predictive of outcome in relation to specific targeted drugs,
13,14
 but these mutations 
are very rare in squamous non-small-cell lung cancer.
1,15
 Thus, although clear advances have been 
made in the first-line treatment of non-squamous non-small-cell lung cancer, especially 
adenocarcinoma, a substantial unmet need persists to improve outcomes for patients with advanced 
squamous non-small-cell lung cancer. We note in this context the recent US FDA approval of 
additional second-line options for patients progressing on or after platinum-based chemotherapy: the 
PD-1 antibody nivolumab for metastatic squamous non-small-cell lung cancer;
16
 and the human 
immunoglobulin G1 VEGFR-2 antibody ramucirumab, in combination with docetaxel, for treatment of 
metastatic non-small-cell lung cancer (including that of squamous histology).
17
 However, only about 
half of patients continue to second-line treatment,
18 
and neither drug is indicated in the first-line setting. 
Most non-small-cell lung cancer tumours express EGFR protein, the high-level expression of which is 
more common in squamous than in non-squamous disease.
19,20
 In the phase 3 FLEX trial,
20
 the 
addition of the chimeric EGFR antibody cetuximab to cisplatin and vinorelbine improved overall 
survival in the first-line treatment of EGFR-expressing, advanced non-small-cell lung cancer, 
unselected (adenocarcinoma, squamous cell carcinoma, and other) by histological subtype (hazard 
ratio [HR] 0∙871 [95% CI 0∙762-0∙9%]; p=0∙044). However, the survival benefit was greatest in the 
subgroup of patients with squamous non-small-cell lung cancer (HR 0∙80 [95% CI 0∙64-1∙00]), but was 
accompanied by a higher frequency of febrile neutropenia overall. 
Necitumumab is a second-generation, recombinant, human immunoglobulin G1 EGFR monoclonal 
antibody that binds to EGFR with high affinity, competing with natural ligands and thereby preventing 
receptor activation and downstream signalling. In murine non-small-cell lung cancer xenograft models, 
the addition of necitumumab to gemcitabine and cisplatin—an established chemotherapy regimen for 
the first-line treatment of advanced squamous non-small-cell lung cancer
21,22
—resulted in a substantial 
increase in anti-tumour activity.
23
 Our randomised, phase 3 study (SQUamous NSCLC treatment with 
the Inhibitor of EGF REceptor [SQUIRE]) assessed the efficacy and safety of necitumumab plus 
gemcitabine and cisplatin as first-line treatment for patients with advanced squamous non-small-cell 
lung cancer. In parallel, the phase 3 INSPIRE study
24
 assessed the efficacy and safety of 
necitumumab plus pemetrexed and cisplatin as first-line treatment for patients with advanced non-
squamous non-small-cell lung cancer. 
 
METHODS 
Study design and participants 
We did this open-label, multicentre, randomised, phase 3 study at 184 investigative sites in 26 
countries (listed in the appendix). The full inclusion and exclusion criteria are provided in the appendix. 
Briefly, patients aged 18 years or older with histologically or cytologically confirmed stage IV 
(according to the AJCC Cancer Staging Manual, seventh edition
25
) squamous non-small-cell lung 
cancer were eligible for enrolment. Other key inclusion criteria were an Eastern Cooperative Oncology 
Group (ECOG) performance status of 0-2 and adequate organ function (white blood cell count ≥3000 
cells per µL, with an absolute neutrophil count ≥1500 cells per µL, platelets ≥100000 per µL, and 
haemoglobin ≥9∙5 g/dL; total bilirubin ≤1∙5x the upper limit of normal [ULN], and aspartate 
aminotransferase and alanine aminotransferase concentrations ≤5∙0xULN in the presence of liver 
metastases or ≤2∙5xULN in the absence of liver metastases and serum creatinine ≤1∙2x ULN or a 
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calculated creatinine clearance >50 mL per min). The availability of archived tumour tissue for the 
analysis of biomarkers was also an inclusion criterion. Key exclusion criteria were: previous 
chemotherapy for advanced non-small-cell lung cancer, major surgery in the 4 weeks before 
randomisation, chest irradiation within the 12 weeks before randomisation, the presence of brain 
metastases that were symptomatic or needed ongoing treatment with steroids or anticonvulsants, 
clinically relevant coronary artery disease or uncontrolled congestive heart failure, and National 
Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0 grade 2 
or worse peripheral neuropathy. 
The study was done in compliance with the Declaration of Helsinki, International Conference on 
Harmonisation Guidelines for Good Clinical Practice, and applicable local regulations. The protocol 
was approved by the ethics committees of all participating centres and all patients provided written 
informed consent before study entry. 
Randomisation and masking 
Patients were randomly assigned (1:1) with a stratified, block randomisation scheme (block size of 
four) via a telephone-based interactive voice response system or interactive web response system to 
receive necitumumab plus gemcitabine and cisplatin or gemcitabine and cisplatin alone. 
Randomisation was done centrally by Pharmaceutical Product Development, LLC (Morrisville, NC, 
USA), and was stratified by ECOG performance status (0-1 vs 2) and geographical region (North 
America, Europe, Australia vs South America, South Africa, India vs eastern Asia). The first dose of 
study drug was planned to be administered within 7 days of randomisation. Neither physicians nor 
patients were masked to group assignment because the expected occurrence of acne-like rash—a 
known class effect of EGFR antibodies—would have unmasked most patients and investigators to 
treatment. An independent data monitoring committee assessed safety during the study on a regular 
basis; this committee was an independent multidisciplinary group consisting of five members (three 
medical oncologists, a drug safety expert, and a biostatistician) with no financial s or other interest in 
the study. 
Procedures 
Chemotherapy comprised a maximum of six 3-week cycles of gemcitabine 1250 mg/m
2
 administered 
intravenously over 30 min on days 1 and 8, and cisplatin 75 mg/m
2
 administered intravenously over 
120 min on day 1. For those assigned to receive it, necitumumab at an absolute dose of 800 mg was 
given intravenously on days 1 and 8, over a minimum of 50 min and before gemcitabine 
administration. Antiemetic premedication for gemcitabine and cisplatin was administered according to 
local practice. Pre-emptive treatment for skin toxicity was allowed only after the first cycle. After the 
end of chemotherapy, patients who were free of disease progression continued to receive single-agent 
necitumumab on the same treatment schedule until radiographic documentation of disease 
progression, the occurrence of toxic effects necessitating cessation, or withdrawal of consent. Dose 
modifications of chemotherapy or necitumumab were allowed according to protocol-defined criteria 
(appendix). 
We assessed tumour response radiographically according to RECIST version 1∙0 criteria
26
 at baseline, 
within 21 days before randomisation, and then every 6 weeks after the first dose of study therapy until 
radiographic documentation of progressive disease. The appendix provides details of the timing of 
laboratory and other assessments. Adverse events were coded according to the Medical Dictionary for 
Regulatory Activities, version 16∙0 and graded with the NCI-CTCAE version 3.0. We assessed patient 
health status with the Lung Cancer Symptom Scale
27
 and the EuroQol-5D.
28
 Tumour EGFR protein 
expression was assessed at a Clinical Laboratory Improvement Amendments (CLIA)-certified 
laboratory by immunohistochemistry with the EGFR PharmDx Kit (Dako, Glostrup, Denmark) and 
assessed independently by two pathologists. The level of EGFR expression was classified by 




The primary endpoint was overall survival, defined as the time from randomisation to death from  any 
cause. 
Secondary endpoints were progression-free survival, defined as the time from randomisation until the 
first radiographic documentation of objective progression or death from any cause; objective response, 
defined as the proportion of patients with a best response of complete or partial response; time to 
treatment failure, defined as time from the date of randomisation until the date of the first radiographic 
documentation of progressive disease, death by any cause, discontinuation of treatment for any 
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reason, or initiation of new anticancer therapy; health status; immunogenicity of necitumumab; safety 




*Primary reasons are listed, †Patients who completed all planned cycles of chemotherapy. ‡Radiologically documented. 
 
Statistical analysis 
We used a two-tailed log-rank test at the 0∙05 significance level and calculated that enrolment of 1080 
patients (with a 5% dropout rate considered) would give 90% power to detect a statistically significant 
difference of overall survival with an HR for necitumumab plus gemcitabine and cisplatin versus 
gemcitabine and cisplatin alone of 0∙8, and a calculated improvement in median overall survival from 
11∙0 months for gemcitabine and cisplatin to 13·75 months for necitumumab plus gemcitabine and 
cisplatin.
31
 We planned to do the final analysis when 844 deaths had occurred. 
We assessed efficacy in the intention-to-treat population that included all randomly assigned patients. 
Safety was assessed in all patients who received at least one dose of study medication and was 
analysed according to actual treatment received. For the primary and secondary analyses, we 
estimated overall and progression-free survival using the Kaplan-Meier method
32
 and we compared 
these outcomes between treatment groups using the log-rank test, stratified by the randomisation 
strata. Overall survival was censored on the last date that the patient was known to be alive. We 
estimated HRs and 95% CIs for necitumumab plus gemcitabine and cisplatin versus gemcitabine and 
cisplatin from stratified Cox proportional hazards models. To formally test the proportional hazards 
assumption, a Cox proportional hazards model was fitted (using the PHREG procedure in SAS) for 
overall survival with the following predictors: treatment, and an interaction term of treatment and log of 
event time. 
We compared the proportion of patients with an objective response in each treatment group using the 
Cochran-Mantel-Haenszel test, adjusting for the stratification variables. In the event that a statistically 
significant result was recorded for the primary endpoint, we planned to use Hochberg's method
33
 to 
adjust for multiplicity of testing in relation to progression-free survival and objective response; if the 
least significant p value from these endpoints was smaller than 0∙05, both null hypotheses could be 
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rejected to claim significance for both. Otherwise, if the most significant p value was smaller than 
0∙025, the null hypothesis was to be rejected for this endpoint and the result judged to be statistically 
significant. 
In a preplanned exploratory analysis, we categorised patients into high (H-score ≥200) and low (H-
score <200) tumour EGFR expression groups, as previously reported,
29 
to investigate whether or not 
an H-score of 200 or higher was predictive for necitumumab benefit. HR calculations for EGFR 
expression subgroups were unstratified, and we calculated p values using likelihood ratio tests. We 
also assessed interactions between treatment groups and EGFR expression subgroups in relation to 
these endpoints using likelihood ratio tests. 
SAS version 9.1.3 was used for data analyses. This study is registered with ClinicalTrials.gov, number 
NCT00981058. 
Role of the funding source 
The funder of the study was responsible for data management, commissioning of laboratory 
investigations, and statistical analysis, and designed the study in conjunction with NT, FRH, LP-A, and 
MAS (the steering committee investigators). The funder interpreted data in collaboration with the 
authors and supported development of the report by providing medical writing and editorial assistance. 
The steering committee had full access to all the data in the study and had the final responsibility for 
the decision to submit for publication. 
 
Table 1: Baseline characteristics 
 Necitumumab plus 




Age (years) 62 (32-84) 62 (32-86) 
Age group (years) 
<65 332 (61%) 340 (62%) 
≥65 to <70 105 (19%) 111 (20%) 
≥70 108 (20%) 97 (18%) 
Sex 
Male 450 (83%) 458 (84%) 
Female 95 (17%) 90 (16%) 
ECOG performance status* 
0 164 (30%) 180 (33%) 
1 332 (61%) 320 (58%) 
2 49 (9%) 47 (9%) 
Ethnic origin 
White 457 (84%) 456 (83%) 
Asian 43 (8%) 42 (8%) 
Black or African-American 5 (<1%) 6 (1%) 
All others 40 (7%) 44 (8%) 
Smoking history 
Smoker 500 (92%) 495 (90%) 
Non-smoker 26 (5%) 27 (5%) 
Ex-light smoker 18 (3%) 26 (5%) 
Missing 1 (<1%) 0 
Geographical region† 
North America, Europe, or 472 (87%) 475 (87%) 
Australia   
South America, South Africa, or, 30 (6%) 32 (6%) 
India   
Eastern Asia 43 (8%) 41 (7%) 
Disease histology 
Squamous 543 (100%) 545 (99%) 
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 Necitumumab plus 




(Continued from previous page)   
Number of metastatic organ systems  
0 0 1 (<1%) 
1 51 (9%) 50 (9%) 
2 193 (35%) 193 (35%) 
>2 301 (55%) 304 (55%) 
Sites of metastatic disease   
Bone 120 (22%) 131 (24%) 
Brain 28 (5%) 30 (5%) 
Liver 109 (20%) 117 (21%) 
Lung 453 (83%) 453 (83%) 
Lymph nodes 431 (79%) 451 (82%) 
Peritoneal 20 (4%) 17 (3%) 
Pleural 149 (27%) 155 (28%) 
Skin 9(2%) 8 (1%) 
Soft tissue 23 (4%) 21 (4%) 
Other 156 (29%) 146 (27%) 
Disease stage at study entry§   
IV¶ 543 (100%) 546 (100%) 
IIIBwithout malignant 1 (<1%) 1 (<1%) 
pleural effusion||   
Missing 1 (<1%) 1 (<1%) 
Previous anticancer therapy   
Surgery 117 (21%) 106 (19%) 
Radiotherapy 42 (8%) 46 (8%) 
Systemic (adjuvant/neoadjuvant) 23 (4%) 17(3%) 
 
Data are median (IQR) or n (%). ECOG=Eastern Cooperative Oncology Group. *One patient with ECOG performance status 3 
was accidentally enrolled and randomly assigned to the gemcitabine and cisplatin group; this patient did not receive treatment, † 
As recorded on the electronic case report form. ‡Squamous cell histology not confirmed. §According to the American Joint 
Committee on Cancer (AJCC) Staging Manual edition effective at the time of randomisation. ¶Includes patients with stage IIIB 
disease with malignant pleural effusion, defined as stage IV in the AJCC Cancer Staging Manual, seventh edition. ||These 
patients with stage IIIB disease without malignant pleural effusion were enrolled accidentally. 
 
RESULTS 
Between Jan 7, 2010, and Feb 22, 2012, we enrolled 1093 eligible patients and randomly assigned 
them to necitumumab plus gemcitabine and cisplatin (n=545) or gemcitabine and cisplatin (n=548). 
Seven patients in each group did not receive study treatment, and therefore the safety population 
comprised 1079 patients (figure 1). The baseline characteristics of the treatment groups were well 
balanced (table 1); notably, 605 (55%) of 1093 patients had metastases to more than two organ 
systems and 96 (9%) had an ECOG performance status of 2. Data cutoff for the present analysis was 
June 17, 2013, at which time 860 (79%) of 1093 patients had died (censoring rate: 233 [21%] of 1093 
patients). 
The median duration of follow-up was 25·2 months (IQR 19∙7-30∙5) in the necitumumab plus 
gemcitabine and cisplatin group and 24∙8 months (19∙4-31∙3) in the gemcitabine and cisplatin group.    
Exposure to chemotherapy was similar in both treatment groups (appendix). The median number of 
cycles of both gemcitabine and cisplatin was six (IQR 3-6) in the necitumumab plus gemcitabine and 
cisplatin group, and five (3-6) in the gemcitabine and cisplatin group. The proportion of patients 
completing at least six cycles of therapy with gemcitabine was 294 (55%) of 538 in the necitumumab 
plus gemcitabine and cisplatin group versus 259 (48%) of 541 in the gemcitabine and cisplatin group, 
and for cisplatin was 286 (53%) of 538 versus 249 (46%) of 541; the median relative dose intensities 
for gemcitabine were 86% (IQR 75-97) versus 86% (74-96) and for cisplatin were 95% (86-99) versus 
95% (86-100), respectively. Patients who continued with necitumumab after the end of chemotherapy 
(n=275) received a median of four additional cycles of treatment (IQR 2-8). Of the 528 patients who 
received necitumumab plus gemcitabine and cisplatin and whose serum was analysed for the 
presence of anti-necitumumab antibodies, 81 (15%) had positive samples at any time during the study 
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and 15 (3%) had positive samples after treatment. The overall frequency of treatment-emergent 
antibody positive samples was judged to be too low to allow any further analysis. 
Necitumumab had the expected pharmacokinetic characteristics of an immunoglobulin G-type 
monoclonal antibody. Accumulation of necitumumab drug concentration across cycles was consistent 
with the previously reported half-life of necitumumab from other studies (data not shown).
34
 
Table 2 summarises the efficacy results. Overall survival was statistically significantly better in the 
necitumumab plus gemcitabine and cisplatin group than in the gemcitabine and cisplatin group 
(stratified HR 0·84 [95% CI 0·74-0·96], p=0∙01). The Kaplan-Meier curves show an early separation in 
favour of the necitumumab plus gemcitabine and cisplatin group from around 3 months that is 
maintained for the duration of the study (figure 2A). The Cox proportional hazards model test indicated 
that no violation of the proportional hazards assumption had occurred. 
In the necitumumab plus gemcitabine and cisplatin group, progression-free survival was also 
statistically significantly improved compared with the gemcitabine and cisplatin group (table 2, figure 
2B) and time to treatment failure was also longer than in the gemcitabine and cisplatin group (stratified 
HR 0·84 [0·75-0·95], p=0·006; table 2). In subgroup analyses of overall and progression-free survival, 
the necitumumab treatment benefit was reported across most subgroups (figure 3A, 3B). Objective 
responses were recorded in similar proportions of patients in the two groups Cochran-Mantel-
Haenszel p=0∙40; table 2). However, disease control was statistically significantly more common in the 
necitumumab plus gemcitabine and cisplatin group than in the gemcitabine and cisplatin group 
(Cochran-Mantel-Haenszel p=0·043; table 2). The numbers of patients who received post-study 
systemic anticancer therapy were similar in the two groups: 258 (47%) of 545 in the necitumumab plus 
gemcitabine and cisplatin group and 245 (45%) of 548 in the gemcitabine and cisplatin group 
(appendix). 
Tissue samples from 982 (90%) of 1093 patients were evaluable by immunohistochemistry for EGFR 
protein expression level. EGFR expression was high (H-score ≥200) in 374 (38%) of 982 cases and 
low (H-score <200) in 608 (62%). We noted that the HR for overall survival for necitumumab plus 
gemcitabine and cisplatin versus gemcitabine and cisplatin alone was more favourable in patients 
bearing tumours with high EGFR expression (HR 0·75 [95% CI 0·60-0·94]) than in those with low 
EGFR expression (0·90 [0·75-1·07]; figure 4). There seemed to be no difference between high and 
low H-score groups when assessing progression-free survival (figure 4). For both overall and 
progression-free survival, interaction tests did not show a significant difference in HRs between the 
high versus low EGFR expression group, consistent with a discriminatory H-score threshold of 200 not 
being predictive of a differential necitumumab effect (figure 4, appendix). Assessment of main-effects 
models using this threshold also did not show significant prognostic associations with overall survival 
(p=0∙67) or progression-free survival (p=0∙95; data not shown). 
388 (72%) of 538 patients in the necitumumab plus gemcitabine and cisplatin group and 333 (62%) of 
541 in the gemcitabine and cisplatin group had one or more grade 3 or worse treatment-emergent 
adverse events (appendix). Grade 3 or worse adverse events that were more common in the 
necitumumab plus gemcitabine and cisplatin group than in the gemcitabine and cisplatin group 
included hypomagnesaemia (47 [9%] of 538 vs six [1%] of 541 patients) and rash (20 [4%] vs one 
[<1%] patient, respectively; appendix). The incidence of grade 3 or worse diarrhoea was similar 
between treatment groups (nine [2%] of 538 vs eight [1%] of 541 patients, respectively). 
We recorded adverse events leading to delay or modification of at least one study drug in 321 (60%) 
of 538 patients in the necitumumab plus gemcitabine and cisplatin group and 312 (58%) of 541 in the 
gemcitabine and cisplatin group. The most frequent of these events in both groups were blood and 
lymphatic system disorders (neutropenia, thrombocytopenia, anaemia, and leukopenia), which 
occurred in 214 (40%) of 538 patients in the necitumumab plus gemcitabine and cisplatin group and 
227 (42%) of 541 in the gemcitabine and cisplatin group. Adverse events leading to discontinuation of 
at least one study drug were reported by 168 (31%) of 538 patients in the necitumumab plus 
gemcitabine and cisplatin group and by 133 (25%) of 541 in the gemcitabine and cisplatin group. 
Neutropenia and thrombocytopenia were the most common reasons for treatment discontinuation of 
any therapy (data not shown). Including events related to disease progression, adverse events with an 
outcome of death were reported for 66 (12%) of 538 patients in the necitumumab plus gemcitabine 
and cisplatin group and 57 (11%) of 541 patients in the gemcitabine and cisplatin group (appendix); 
these were deemed to be related to study drugs in 15 (3%) and ten (2%) patients, respectively. 
Serious adverse events were reported more frequently in patients in the necitumumab plus 
gemcitabine and cisplatin group (257 [48%] of 538 patients) than in the gemcitabine and cisplatin 
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group (203 [38%] of 541). 
To further assess safety, adverse events of interest were defined on the basis of the known safety 
profiles of other EGFR antibodies and previous clinical experience with necitumumab, gemcitabine, or 
cisplatin (table 3). Events pooled under the categories of skin reactions, rash, hypomagnesaemia, and 
venous thromboembolic events were reported more frequently (any grade and grade 3 or worse) in the 
necitumumab plus gemcitabine and cisplatin group than in the gemcitabine and cisplatin group. For 
example, the incidence of venous thromboembolic events of any grade was 49 (9%) of 538 patients in 
the necitumumab plus gemcitabine and cisplatin group versus 29 (5%) of 541 patients in the 
gemcitabine and cisplatin group, whereas the incidence of grade 3 or worse of these events was 27 
(5%) versus 14 (3%), respectively. Notably, the rate of fatal venous or arterial thromboembolic events 
did not differ significantly between treatment groups (<1% in both groups). Overall, the safety profile 
was generally similar for subgroups of patients aged younger than 70 years and those aged 70 years 
or older (appendix). 
Analyses of health status did not suggest a consistent or compelling difference between the treatment 
groups. In particular, time to deterioration for the six major symptoms associated with lung 
malignancies, as measured on the Lung Cancer Symptom Scale, was generally similar between 
treatment groups, which indicates that the addition of necitumumab to gemcitabine and cisplatin was 




Table2: Efficacy endpoints 
 Necitumumab plus 






Deaths 418 (77%) 442 (81%) 
Median overall survival, months (95% CI) 11·5 (10·4-12·6) 9·9 (8·9-11·1)    
1 year overall survival (95% CI) 48% (43-52) 43% (39-47) 
2 year overall survival (95% CI) 20% (16-24) 17% (13-20) 
Progression-free survival 
Deaths or disease progressions 431 (79%) 417 (76%) 
Median progression-free survival, months 
(95% CI) 
5·7 (5·6-6·0) 5·5(4·8-5·6) 
3 month progression-free survival (95% CI) 79% (76-83) 73% (68-76) 
6 month progression-free survival (95% CI) 45% (40-49) 37% (33-42) 
Time to treatment failure 
Events 529 (97%) 528 (96%) 
Mediantime,months(95%CI) 4·3 (4·2-4·8) 3·6 (3·3-4·1) 
Response 
Best overall response   
   Complete response 0 3 (<1%) 
   Partial response 170 (31%) 155 (28%) 
   Stable disease 276 (51%) 264 (48%) 
   Progressive disease 41 (8%) 55 (10%) 
   Not evaluable 4 (<1%) 12 (2%) 
   Not assessed 54 (10%) 59 (11%) 
Patients achieving an objective response (%; 
95% CI) 
170 (31%; 27-35) 158 (29%; 25-33)  
Patients achieving disease control 
(%;95%CI)* 
446 (82%; 78-85) 422 (77%; 73-80) 
Data are n (%) unless otherwise indicated. *Defined as the proportion of patients who had a best response of complete 
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Figure 2: Kaplan-Meier estimates of overall and progression-free survival 
(A) Overall survival and (B) progression-free survival in the intention-to-treat population.The stepped 
appearance of the Kaplan-Meier plot is a function of the strict assessment of response status every 6 
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Figure3: Subgroup analyses 
(A) Overall survival and (B) progression-free survival in subgroups defined by baseline characteristics. 
HR=hazard ratio. ECOG=Eastern Cooperative Oncology Group. *Stratified HR for intention-to-treat 
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Figure4 : Forest plots of overall (A) and progression-free (B) survival in high (H-score ≥200) and 
low (H-score <200) tumour EGFR expression groups 





Table 3: Adverse events of interest 
 Necitumumab plus gemcitabine and 
cisplatin (n=538) 
Gemcitabine and cisplatin (n=541) 
 Grade 1-2 Grade 3 Grade 4 Grade 5 Grade 1-2 Grade 3 Grade 4 Grade 5 
Neutropenia 104 (19%) 97 (18%) 34(6%) 0 99 (18%) 106 
(20%) 
43 (8%) 0 
Febrile neutropenia 2 (<1%) 3 (<1%) 1 (<1%) 0 1 (<1%) 6 (1%) 1 (<1%) 0 
Anaemia 168 (31%) 55 (10%) 2 (<1%) 0 189 (35%) 56 (10%) 3 (<1%) 0 
Thrombocytopenia 62 (12%) 38 (7%) 17 (3%) 0 88 (16%) 35(6%) 23 (4%) 0 
Diarrhoea 75 (14%) 9 (2%) 0 0 53 (10%) 6 (1%) 2 (<1%) 0 
Fatigue 190 (35%) 38 (7%) 1 (<1%) 0 192 (35%) 36 (7%) 2 (<1%) 0 
Hypomagnesaemia 118 (22%) 37 (7%) 13 (2%) 0 79 (15%) 6 (1%) 0 0 
Skin reactions 380 (71%) 44 (8%) 0 0 61 (11%) 3 (<1%) 0 0 
   Rash 372 (69%) 38 (7%) 0 0 53 (10%) 2 (<1%) 0 0 
Hypersensitivity/infusion-
related reaction 
6 (1%) 2 (<1%) 0 0 11 (2%) 0 0 0 
Conjunctivitis 38 (7%) 2 (<1%) 0 0 12 (2%) 0 0 0 
Interstitial lung disease 
(pneumonitis) 
3 (<1%) 1 (<1%) 0 1 (<1%) 1 (<1%) 3 (<1%) 0 0 
Arterial thromboembolic 
events 
8 (1%) 13 (2%) 5 (<1%) 3 (<1%) 10 (2%) 8(1%) 2 (<1%) 1 (<1%) 
Venous thromboembolic 
events 
22 (4%) 19 (4%) 7 (1%) 1 (<1%) 15 (3%) 5 (<1%) 8 (1%) 1 (<1%) 
Data are n (%). The table shows adverse events of interest possibly related to study treatment, according to either composite 
categories or preferred terms (febrile neutropenia and diarrhoea only). Adverse events of grade 1-2 in 10% or more of patients 
in either treatment group, or grades 3-5 in one or more patients in either treatment group, are presented in the appendix. 
 
DISCUSSION 
Our findings show that the addition of necitumumab to gemcitabine and cisplatin was associated with 
a statistically significant improvement in overall survival in patients with advanced squamous non-
small-cell lung cancer. This treatment effect was supported by a corresponding statistically significant 
improvement in progression-free survival. In this broad patient population, which is typical of one seen 
in clinical practice, outcome improvements were recorded across major subgroups at a similar level of 
magnitude. Notably, a necitumumab benefit was apparent for patients with an ECOG performance 
status of 2. Although the subgroup analyses provided no evidence that patients aged 70 years or older 
benefited from the addition of necitumumab to gemcitabine and cisplatin, we cannot exclude the 
possibility that this is a chance finding. The safety profile of necitumumab combined with gemcitabine 
and cisplatin was acceptable and consistent across patient subgroups, including in elderly patients.
36
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These findings are consistent with results from previous clinical trials and a meta-analysis of individual 
patient data from four randomised studies in which chemotherapy plus the chimeric EGFR antibody 
cetuximab, which interacts with a similar EGFR epitope to necitumumab,
37
 was compared with 
chemotherapy alone in patients with non-small-cell lung cancer.
38
 The meta-analysis showed a clear 
overall survival benefit for cetuximab in patients with squamous non-small-cell lung cancer (HR 0·77 
[95% CI 0·64-0·93]). By contrast, in the parallel phase 3 INSPIRE trial,
24
 the addition of necitumumab 
to a first-line pemetrexed and cisplatin treatment regimen did not improve overall survival in patients 
with non-squamous non-small-cell lung cancer. 
The early divergence of the Kaplan-Meier plots for overall survival (at around 3 months) and 
progression-free survival (at around 2 months) in our study suggests a clear benefit of necitumumab, 
which starts during the chemotherapy phase of treatment. However, the study design does not allow 
us to ascertain the benefit of the continued administration of necitumumab after the end of 
chemotherapy. Since roughly equal numbers of patients in the treatment groups received post-study 
systemic anticancer therapy and in view of the fact that the type of post-study systemic anticancer 
therapy also seemed to be reasonably balanced between the treatment groups, our data suggest that 
the overall survival benefit in the necitumumab plus gemcitabine and cisplatin group is based on the 
addition of necitumumab to chemotherapy, rather than an imbalance in post-study systemic anticancer 
therapy. 
The addition of necitumumab to gemcitabine and cisplatin was associated with an increased 
occurrence of grade 3 or worse adverse events. This finding was especially apparent in relation to 
hypomagnesaemia and skin reactions, which are manageable side-effects typically associated with 
EGFR antibodies.
39,40
 Also in line with expectations for such agents when combined with platinum-
based chemotherapy
41
 venous thromboembolic events were more common in the necitumumab plus 
gemcitabine and cisplatin group than in the control group. However, importantly, the incidence of fatal 
thromboembolic events did not differ between treatment groups. Moreover, no relevant increase in the 
incidence of toxicities typically associated with chemotherapy occurred in the necitumumab plus 
gemcitabine and cisplatin group. By contrast with data from the FLEX trial,
20
 febrile neutropenia was 
reported rarely and the incidence was essentially balanced between treatment groups, as was that of 
grade 3 or worse neutropenia. In line with expectations for a human antibody
42,43
 no increases in the 
overall incidence of hypersensitivity or infusion-related reactions associated with the administration of 
necitumumab were reported. 
High-level expression of EGFR protein in advanced non-small-cell lung cancer (tumour H-score 
≥200) might 
be predictive for the overall survival benefit associated with the addition of cetuximab to first-line 
chemotherapy
29 
In a prospectively planned analysis, we therefore explored whether or not an H-score 
of 200 or higher was of predictive value in patients receiving necitumumab plus gemcitabine and 
cisplatin. We noted that interaction test p values for treatment by EGFR expression level for both 
overall and progression-free survival were not significant. These findings are consistent with a 
discriminatory H-score of 200 not being of predictive value. Notably, a discriminatory EGFR H-score of 
200 was also not predictive for treatment efficacy in patients with non-squamous non-small-cell lung 
cancer who received necitumumab plus pemetrexed and cisplatin.
24
 Exploratory analyses in this study 
for potential associations between efficacy and another potential EGFR pathway or non-small-cell lung 
cancer biomarker, or the early occurrence of skin rash are ongoing and will be reported elsewhere. 
In conclusion, to the best of our knowledge, SQUIRE is the first trial of first-line treatment for advanced 
squamous non-small-cell lung cancer to show that the addition of a targeted agent to a platinum-based 
doublet improves survival. These efficacy data and the acceptable safety profile of necitumumab 
suggest a favourable benefit-to-risk ratio for this combination treatment. 
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